BSE Live
Sep 05, 16:01Prev. Close
1369.90
Open Price
1371.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 05, 15:58Prev. Close
1370.70
Open Price
1369.10
Bid Price (Qty.)
1372.70 (26)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Emcure Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | |||||
Revenue From Operations [Gross] | 7,808.27 | 6,581.99 | 5,931.08 | 5,766.20 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 7,808.27 | 6,581.99 | 5,931.08 | 5,766.20 | |
Total Operating Revenues | 7,896.00 | 6,658.25 | 5,985.81 | 5,855.39 | |
Other Income | 67.26 | 56.99 | 45.91 | 63.47 | |
Total Revenue | 7,963.26 | 6,715.24 | 6,031.72 | 5,918.86 | |
EXPENSES | |||||
Cost Of Materials Consumed | 1,526.90 | 1,333.13 | 1,146.59 | 1,296.10 | |
Purchase Of Stock-In Trade | 1,883.24 | 1,332.48 | 1,047.25 | 1,082.45 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FGWIP And Stock In Trade | -263.53 | -190.19 | 66.69 | -145.40 | |
Employee Benefit Expenses | 1,446.29 | 1,292.08 | 1,117.33 | 1,011.82 | |
Finance Costs | 175.78 | 237.15 | 213.61 | 175.98 | |
Depreciation And Amortisation Expenses | 384.13 | 312.41 | 260.12 | 244.86 | |
Other Expenses | 1,828.72 | 1,661.03 | 1,426.77 | 1,280.50 | |
Total Expenses | 6,981.53 | 5,978.08 | 5,278.36 | 4,946.31 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 981.73 | 737.16 | 753.36 | 972.55 | |
Exceptional Items | -10.38 | -9.93 | -6.15 | 0.00 | |
Profit/Loss Before Tax | 971.35 | 727.23 | 747.22 | 972.55 | |
Tax Expenses-Continued Operations | |||||
Current Tax | 292.16 | 209.64 | 173.30 | 286.05 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -28.28 | -9.99 | 12.07 | -16.06 | |
Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 263.88 | 199.65 | 185.37 | 269.99 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 707.47 | 527.58 | 561.85 | 702.56 | |
Profit/Loss From Continuing Operations | 707.47 | 527.58 | 561.85 | 702.56 | |
Profit/Loss For The Period | 707.47 | 527.58 | 561.85 | 702.56 | |
Minority Interest | -26.14 | -29.39 | -29.83 | -40.36 | |
Consolidated Profit/Loss After MI And Associates | 681.33 | 498.18 | 532.02 | 662.20 | |
OTHER ADDITIONAL INFORMATION | |||||
EARNINGS PER SHARE | |||||
Basic EPS (Rs.) | 36.00 | 28.00 | 29.00 | 37.00 | |
Diluted EPS (Rs.) | 36.00 | 28.00 | 29.00 | 37.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | |||||
Equity Share Dividend | 0.00 | 54.26 | 36.17 | 54.26 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
07.08.2025
Emcure Pharmace Standalone June 2025 Net Sales at Rs 1,096.57 crore, up 13.01% Y-o-Y
17.07.2025
10.07.2025
07.07.2025
07.08.2025
Emcure Pharmace Standalone June 2025 Net Sales at Rs 1,096.57 crore, up 13.01% Y-o-Y
27.05.2025
Emcure Pharmace Consolidated March 2025 Net Sales at Rs 2,116.25 crore, up 19.47% Y-o-Y
23.05.2025
Emcure Pharmace Standalone March 2025 Net Sales at Rs 1,278.19 crore, up 41.62% Y-o-Y
12.02.2025
Emcure Pharmace Standalone December 2024 Net Sales at Rs 1,028.81 crore, up 18.23% Y-o-Y